NKTR
Nektar Therapeutics
Healthcare — Biotechnology
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Price History
Fundamentals
| Market Cap | $2.39B |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.95 |
| EPS (TTM) | $-7.93 |
| Dividend Yield | - |
| Profit Margin | -284.18% |
| Revenue Growth | 3.80% |
| ROE | -53.60% |
| Debt/Equity | 24.89 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $153.22 |
| Analysts | 9 |
| Next Earnings | Aug 13, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 57.0 |
| Beta | 1.14 |
| SMA 20 | $70.01 |
| SMA 40 | $66.05 |
| 52-Week High | $109.00 |
| 52-Week Low | $21.02 |
| 50-Day Avg | $65.78 |
| 200-Day Avg | $63.03 |
| Avg Volume | 998.8K |
| Volume | 475.1K |
Performance Analysis
NEUTRALNKTR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 04:14 UTC
Back to Screener Export Report